- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05163834
Immune Response to PNEUMOVAX 23 in Healthy Adults Receiving Efgartigimod IV
March 16, 2022 updated by: argenx
A Randomized, Open-label, Placebo-Controlled, Parallel-Group Study to Evaluate the Immune Response to the Polyvalent Pneumococcal Vaccine (PNEUMOVAX 23) in Healthy Participants Receiving Intravenous Efgartigimod or Placebo
This is a randomized, open-label, placebo-controlled phase 1 study in healthy adult volunteers to provide information regarding vaccination with a common pneumococcal polysaccharide vaccine while receiving efgartigimod.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
36
Phase
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Groningen, Netherlands, 9728 NZ
- Investigator Site 1
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (ADULT, OLDER_ADULT)
Accepts Healthy Volunteers
Yes
Genders Eligible for Study
All
Description
Inclusion Criteria:
- At least 18 years of age at the time of signing the informed consent form (ICF)
- Healthy as determined by medical evaluation including medical history, physical examination, laboratory tests, and cardiac monitoring
- Body mass index (BMI) between 18 kg/m2 to 30 kg/m2 (inclusive)
- Contraceptive use by men and women should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies.
- Male participants must agree not to donate sperm from the time the ICF was signed until the end of the study
- Women of childbearing potential must have a negative serum pregnancy test at screening and a negative urine pregnancy test at baseline before study intervention can be administered.
- Capable of giving signed informed consent, which includes compliance with the requirements and restrictions listed in the ICF and in this protocol
- Abstains from smoking for at least 3 months prior to screening
- Negative urine drug screen and negative alcohol urine test
- Agrees to restrict excessive strenuous physical activities 96 hours prior to screening, 96 hours prior to the visits in the treatment period, and 96 hours prior to the visits in follow-up period.
Exclusion Criteria:
- Clinically significant active or chronic bacterial, viral, including or fungal infection at day -1
- History of malignancy unless deemed cured by adequate treatment with no evidence of recurrence for ≥3 years before the first administration of study intervention. Participants with the following cancers can be included at any time: Adequately treated basal cell or squamous cell skin cancer ; Carcinoma in situ of the cervix and Carcinoma in situ of the breast; Incidental histological finding of prostate cancer (TNM stage T1a or T1b).
- Clinical evidence of other significant serious diseases, a recent major surgery, or any other condition that, in the opinion of the investigator, could confound the results of the study or put the participant at undue risk
- Use of an investigational product within 2 months or 5 half-lives (whichever is longer) before the first dose of study intervention; Use of any monoclonal antibody within 3 months prior to the initial study intervention administration; Use of any systemic immunosuppressant agent within 6 months prior to the initial study intervention administration; Use of any systemic steroid within 3 months prior to the initial study intervention administration; Use of B-cell depleting agents in the year before the initial screening visit
- Previously participated in a clinical study with efgartigimod and received at least 1 dose of efgartigimod
- Positive serum test screening for an active viral infection with any of the following conditions: Hepatitis B virus (HBV), Hepatitis C virus (HCV), Human immunodeficiency virus (HIV) based on test results that are associated with an acquired immunodeficiency syndrome (AIDS)-defining condition, or a CD4 count ≤200 cells/mm3.
- Positive nasopharyngeal swab antigen test for SARS-CoV-2 on day -1. Any contact with SARS-CoV-2 positive or COVID-19 patients within the last 2 weeks prior to admission.
- Total IgG ≤6 g/L at screening
- Current or history of (ie, within 12 months of screening) alcohol, drug, or medication abuse
- Known hypersensitivity reaction to any of the excipients of study intervention, the PNEUMOVAX 23 vaccine, or any of its excipients
- Pregnant or lactating females and those who intend to become pregnant during the study or within 90 days after the last dose of study intervention
- Received a live or live-attenuated vaccine less than 4 weeks before screening. The receipt of any inactivated, subunit, polysaccharide, or conjugate vaccine at any time before screening is not considered exclusionary
- Received a pneumococcal vaccine within the past 10 years
- Documented pneumococcal infection within the past 5 years prior to first administration of the study intervention
- Has a clinically relevant abnormality detected on ECG recording regarding either rhythm or conduction. A first-degree heart block or sinus arrhythmia will not be considered a significant abnormality.
- Had significant blood loss (including blood donation ≥500 mL) within 12 weeks prior to the (first) study intervention administration
- Has any condition impairing phlebotomy
- Is an employee of the investigator or study center, with direct involvement in the proposed study or other studies under the direction of that investigator or study center, as well as a family member of an employee or the investigator
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: OTHER
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: Efgartigimod-1
Weekly efgartigimod infusions and the pneumovax 23 vaccine on day 22
|
intravenous infusion of efgartigimod
PNEUMOVAX 23 vaccine
|
EXPERIMENTAL: Efgartigimod-2
Weekly efgartigimod infusions and the pneumovax 23 vaccine on day 36
|
intravenous infusion of efgartigimod
PNEUMOVAX 23 vaccine
|
PLACEBO_COMPARATOR: Placebo
Weekly placebo infusions and the pneumovax 23 vaccine on day 22
|
PNEUMOVAX 23 vaccine
intravenous infusion of placebo
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Variation in the immune response assessed by comparing pneumococcal capsular polysaccharide (PCP) titers pre- and postadministration of the PNEUMOVAX 23 vaccine between study arms
Time Frame: throughout the study (up to 12 weeks)
|
throughout the study (up to 12 weeks)
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (ACTUAL)
November 17, 2021
Primary Completion (ACTUAL)
March 8, 2022
Study Completion (ACTUAL)
March 8, 2022
Study Registration Dates
First Submitted
November 23, 2021
First Submitted That Met QC Criteria
December 17, 2021
First Posted (ACTUAL)
December 20, 2021
Study Record Updates
Last Update Posted (ACTUAL)
March 17, 2022
Last Update Submitted That Met QC Criteria
March 16, 2022
Last Verified
March 1, 2022
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- ARGX-113-2102
- 2021-004878-53 (EUDRACT_NUMBER)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
UNDECIDED
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Healthy Volunteers
-
AstraZenecaCompletedHealthy Elderly Volunteers | Healthy Young VolunteersUnited States
-
Syndax PharmaceuticalsCompletedHealthy Volunteers | Volunteers | Normal Volunteers | Human VolunteersUnited States
-
Syndax PharmaceuticalsCompletedHealthy Volunteers | Volunteers | Normal Volunteers | Human VolunteersUnited States
-
University Hospital, Clermont-FerrandUnite de Nutrition Humaine UMR 1019- INRAE; Unite MetaGenoPolis INRAE; France...CompletedHealthy Volunteers | Frail VolunteersFrance
-
Newcastle UniversityCompletedGI Glycaemic Index Healthy Volunteers | GL Glycaemic Load Healthy VolunteersUnited Kingdom
-
Galera Therapeutics, Inc.Syneos HealthCompleted
-
Galera Therapeutics, Inc.Syneos HealthCompletedHealthy | Healthy VolunteersAustralia
-
Galera Therapeutics, Inc.CelerionCompletedHealthy | Healthy VolunteersUnited States
-
Maastricht University Medical CenterCompletedHealthy Volunteers | Healthy Subjects | Healthy AdultsNetherlands
-
PMV Pharmaceuticals, IncRecruitingHealthy VolunteersUnited States
Clinical Trials on Efgartigimod
-
argenxCompleted
-
argenxRecruitingGeneralized Myasthenia GravisUnited States, Netherlands, Belgium, Poland, United Kingdom
-
argenxCompletedGeneralized Myasthenia GravisSpain, United States, Belgium, Georgia, Germany, Hungary, Italy, Japan, Netherlands, Poland, Russian Federation
-
argenxNot yet recruiting
-
argenxIqvia Pty LtdRecruitingPrimary Sjögren's SyndromeBelgium, Hungary, Poland
-
argenxIqvia Pty LtdRecruitingPost-COVID Postural Orthostatic Tachycardia Syndrome Postural Orthostatic Tachycardia SyndromeUnited States
-
argenxNot yet recruiting
-
argenxRecruitingGeneralized Myasthenia GravisUnited Kingdom, Spain, United States, Austria, Germany, Belgium, Italy, Netherlands, France, Georgia, Poland, Canada
-
argenxIqvia Pty LtdActive, not recruitingPostural Orthostatic Tachycardia SyndromeUnited States
-
Shanghai Zhongshan HospitalNot yet recruitingMyasthenia Gravis